AbCellera Biologics Inc. develops antibody-based medicines as a clinical-stage biotechnology company. Its updates center on antibody discovery and development programs in endocrinology, women’s health, immunology, oncology, and other areas, including work on complex targets such as GPCRs and ion channels.
Recurring news themes include clinical disclosures for ABCL635, an antibody therapeutic targeting NK3R for the non-hormonal treatment of moderate-to-severe vasomotor symptoms associated with menopause. Company announcements also cover financial results, earnings-call materials, investor conference participation, platform and manufacturing updates, and patent licensing or litigation-resolution developments.
AbCellera (Nasdaq: ABCL) has initiated a Phase 1 clinical trial for ABCL575, dosing the first participants in a study targeting moderate-to-severe atopic dermatitis. The investigational antibody therapy is engineered with unique characteristics, including Fc-silencing and half-life extension, allowing for a dosing interval of once every six months - a significant improvement over current clinical-stage alternatives.
The trial (NCT07108894) is designed as a randomized, placebo-controlled, double-blind study evaluating safety and tolerability in healthy participants receiving subcutaneous doses. The company expects to report data from this study in mid 2026. The therapy, which targets OX40 ligand, shows potential for treating other inflammatory and autoimmune conditions beyond atopic dermatitis.
AbCellera (Nasdaq: ABCL) announced its participation in two upcoming investor conferences in September 2025. The company will attend the Wells Fargo Healthcare Conference from September 3-5, and the Morgan Stanley Annual Global Healthcare Conference from September 8-10. Additional information can be found on AbCellera's Investor Relations website.
AbCellera (Nasdaq: ABCL) reported Q2 2025 financial results and announced a significant milestone with the initiation of dosing in a Phase 1 clinical trial for ABCL635, targeting vasomotor symptoms in menopause. The company reported revenue of $17.1M (up from $7.3M in Q2 2024) and a net loss of $34.7M.
Key developments include authorization for Phase 1 trials of both ABCL635 and ABCL575, advancing ABCL688 into IND-enabling studies, and reaching 102 partner-initiated programs. The company maintains strong liquidity with $753M available, including $580M in cash and $173M in government funding.
AbCellera (NASDAQ: ABCL) has scheduled its second quarter 2025 financial results announcement for Thursday, August 7, 2025. The company will host an earnings conference call at 2:00 PM PT / 5:00 PM ET on the same day. Investors can access the live audio webcast through AbCellera's Investor Relations website, where a replay will also be available after the call.
AbCellera (ABCL) has received authorization from Health Canada to proceed with Phase 1 clinical trials for ABCL635, their investigational antibody treatment targeting neurokinin 3 receptor (NK3R). The drug is being developed as a non-hormonal treatment for moderate-to-severe vasomotor symptoms (VMS), commonly known as hot flashes, in menopausal women.
The Phase 1 trial, scheduled to begin in Q3 2025, will evaluate ABCL635's safety, pharmacokinetics, and pharmacodynamics in both healthy participants and postmenopausal women experiencing moderate-to-severe VMS. The company aims to provide a long-acting treatment option for millions of women affected by these disruptive menopausal symptoms.
AbCellera (ABCL) presented preclinical data for ABCL575, a novel anti-OX40L monoclonal antibody developed for treating moderate-to-severe atopic dermatitis, at the 2025 SID Annual Meeting. The drug demonstrated potent inhibition of inflammatory pathways and showed promising characteristics including:
- Equivalent functional activity to leading clinical benchmarks - Modified Fc domain supporting Fc-silencing and half-life extension - Predicted human half-life exceeding 60 days - Positive nonclinical safety profile - Favorable stability at high concentration
The company plans to advance ABCL575 to clinical trials within 2025, positioning it as a potential best-in-class treatment for atopic dermatitis with less frequent dosing requirements.
AbCellera (ABCL) reported its Q1 2025 financial results, highlighting the introduction of ABCL635, a potential first-in-class antibody for non-hormonal treatment of menopausal hot flashes. The company posted revenue of $4.2 million, down from $10.0 million in Q1 2024, and a net loss of $45.6 million ($0.15 per share) compared to $40.6 million loss in Q1 2024.
The company reached 97 partner-initiated program starts with downstreams (up 8% YoY) and increased its molecules in the clinic to 16 (up 23% YoY). AbCellera maintains strong liquidity with $810 million available, including $633 million in cash and equivalents and $178 million in non-dilutive government funding. The company plans to initiate Phase 1 clinical trials for both ABCL635 and ABCL575 in H2 2025.
AbCellera has unveiled promising preclinical data for its PSMA x CD3 T-cell engagers (TCEs) at the AACR Annual Meeting 2025. The research focuses on potential treatments for metastatic castration-resistant prostate cancer (mCRPC).
Key findings include:
- Potent tumor-cell killing ability, with one molecule showing ~10x higher EC50 than benchmark
- Sustained activity across four rounds of serial T-cell killing
- Significant tumor growth inhibition in xenograft mouse models
- Enhanced potency potential when combined with costimulatory PSMA x CD28 bispecifics
This marks the first demonstration of AbCellera's novel CD3-binders generating molecules with strong anti-tumor efficacy in vivo. The company's TCE platform strategy combines diverse CD3 and tumor-binding antibodies to develop optimized therapeutic candidates.